Toosendanin, a late-stage autophagy inhibitor, sensitizes triple-negative breast cancer to irinotecan chemotherapy

Shuang Zhang, Yu Dong, Xiuping Chen, Chris Soon Heng Tan, Min Li, Kai Miao, Jia Hong Lu*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Toosendanin, a late-stage autophagy inhibitor, sensitizes triple-negative breast cancer to irinotecan chemotherapy'. Together they form a unique fingerprint.

Medicine & Life Sciences